Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.8333.

A number of equities research analysts have commented on PYXS shares. Wedbush started coverage on Pyxis Oncology in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, March 24th. Stifel Nicolaus reduced their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Weiss Ratings raised Pyxis Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Finally, Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the company. Maia Wealth LLC acquired a new stake in Pyxis Oncology in the fourth quarter valued at approximately $25,000. Fox Run Management L.L.C. bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $26,000. Engineers Gate Manager LP bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $26,000. Avanza Fonder AB bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $31,000. Finally, LPL Financial LLC lifted its holdings in shares of Pyxis Oncology by 150.7% in the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after purchasing an additional 21,100 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $3.01 on Friday. The business has a 50 day simple moving average of $2.00 and a 200 day simple moving average of $1.75. Pyxis Oncology has a one year low of $0.97 and a one year high of $5.55. The stock has a market capitalization of $190.68 million, a P/E ratio of -2.30 and a beta of 1.42.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Equities analysts expect that Pyxis Oncology will post -1.23 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.